Loading clinical trials...

Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT03696771

Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer

A first-in-human study using NJH395 in non-breast HER2-positive advanced malignancies

Lead sponsor: Novartis Pharmaceuticals•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment18

Start dateDec 2018

Last updatedFeb 4, 2022

Condition

NON-breast HER2+ Malignancies

Locations shown

University of Texas MD Anderson Cancer Center

Houston, Texas

Novartis Investigative Site

Milan, MI

Novartis Investigative Site

Kashiwa, Chiba

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 4, 2022Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions